GleamWall
中文EN

VREOF Vireo Growth Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1771706 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY255.9%
TTM net income YoY-2.2%
TTM EPS YoY149.6%
Revenue 3-yr CAGR101.0%
Net income 3-yr CAGR—

Margins

Gross margin47.4%
Operating margin1.3%
Net margin-9.6%
FCF margin-14.6%
EBITDA margin5.4%

Returns

ROE-17.5%
ROA-6.2%
ROIC (approx.)3.3%
Asset turnover0.64x

Leverage & solvency

Liabilities / assets65.3%
Debt / equity0.00x
Current ratio1.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.58x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue20.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$253.70M$209.30M$106.20M$104.51M$91.70M$48.10M$24.50M$25.02M
Gross profit$107.80M$95.30M$59.30M$56.88M$37.40M$20.40M$12.40M$12.65M
SG&A expense$82.00M$75.80M$30.80M$31.58M$33.70M$16.60M$7.40M$6.54M
Operating income$7.60M-$6.30M$9.00M-$1.81M$800,000-$2.00M$2.00M-$841,550
Interest expense$11.50M$7.60M——$3.90M$4.70M$7.60M$7.58M
Pretax income$4.00M$14.20M-$4.20M-$12.05M-$13.00M-$10.10M-$4.80M-$11.36M
Net income-$24.00M-$100,000-$20.30M-$20.37M-$26.30M-$14.90M-$6.50M-$15.70M
EBITDA$13.70M-$400,000$13.00M$10.10M$3.20M-$700,000$2.60M-$205,967
EPS (basic)-0.490.00-0.02—-0.83-0.80-0.02—
EPS (diluted)-0.490.00-0.02—-0.83-0.80-0.02—
Weighted avg. shares (diluted)49.22M45.09M1.08B—31.66M18.64M366.80M—
Balance sheet
Cash & equivalents$106.80M$122.70M$137.80M$122.50M$117.50M$106.10M$86.20M$91.60M
Short-term investments—$1.00M$1.00M$1.00M$1.01M$1.00M——
Receivables——$14.10M$12.70M$11.19M$9.14M$2.42M$2.87M
Inventory$158.80M$149.40M$76.10M$60.00M$53.90M$63.03M$23.34M$21.67M
Current assets$382.30M$394.50M$258.30M$305.10M$307.96M$312.79M$228.43M$230.37M
PP&E, net$282.80M$280.70M$232.30M$217.50M$121.24M$110.66M$32.84M$32.31M
Goodwill$178.10M$161.10M$123.80M$87.50M$97.29M$72.64M—$0
Intangibles$268.00M$218.70M$194.00M$117.50M$89.65M$86.17M$7.69M$7.90M
Total assets$1.42B$1.27B$928.80M$817.20M$678.92M$659.34M$277.05M$278.86M
Current liabilities$195.10M$390.70M$215.80M$191.70M$234.91M$243.52M$137.66M$135.47M
Total liabilities$929.80M$831.20M$634.70M$509.80M$432.61M$390.76M$226.61M$223.30M
Shareholders' equity$494.80M$442.50M$294.10M$307.40M$246.30M$268.60M$50.50M$55.50M
Cash flow statement
Operating cash flow$4.50M$2.40M$11.90M$18.66M-$6.80M-$4.80M-$3.40M-$6.44M
Capital expenditure$6.80M$108.20M$10.80M$9.86M$13.70M$3.70M$1.10M$2.72M
Free cash flow-$2.30M-$105.80M$1.10M$8.79M-$20.50M-$8.50M-$4.50M-$9.16M
Investing cash flow-$7.70M-$69.70M$8.00M-$9.42M-$14.70M$34.00M-$1.10M-$2.61M
Financing cash flow-$12.70M$52.20M-$4.60M-$4.28M$32.90M-$9.30M-$900,000$93.38M
Depreciation & amortization$6.10M$5.90M$4.00M$11.91M$2.40M$1.30M$600,000$635,583
Stock-based compensation$6.00M$7.50M$7.00M$9.16M$4.01M$4.20M$1.50M$2.20M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.